Profil
David Nakasone is Senior Director-Investor Relations at Tarsus Pharmaceuticals, Inc. since 2021.
Formerly, Mr. Nakasone was Director-Investor Relations at Lineage Cell Therapeutics, Inc., Associate Director-Investor Relations at Ionis Pharmaceuticals, Inc., and Investor Relations Contact at Allergan, Inc. from 2013 to 2015.
Education includes undergraduate studies at San Diego State University.
Aktiva positioner av David Nakasone
| Företag | Position | Start |
|---|---|---|
| TARSUS PHARMACEUTICALS, INC. | Investor Relations Kontakt | 2021-09-01 |
Tidigare kända positioner av David Nakasone
| Företag | Position | Slut |
|---|---|---|
| ALLERGAN, INC. | Offentlig kommunikationskontakt | 2015-06-01 |
| IONIS PHARMACEUTICALS, INC. | Offentlig kommunikationskontakt | - |
| LINEAGE CELL THERAPEUTICS, INC. | Investor Relations Kontakt | - |
David Nakasones utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Allergan, Inc.
Allergan, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutic products for retinal & neurological diseases and disorders and oncology | Health Technology |
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs | Health Technology |
San Diego State University
San Diego State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapeutic drugs for blepharitis | Health Technology |
















